{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:58:47Z","timestamp":1789981127004,"version":"4.0.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,5,10]],"date-time":"2014-05-10T00:00:00Z","timestamp":1399680000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s00280-014-2477-x","type":"journal-article","created":{"date-parts":[[2014,5,9]],"date-time":"2014-05-09T10:30:53Z","timestamp":1399631453000},"page":"211-215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with 99mTc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin"],"prefix":"10.1007","volume":"74","author":[{"given":"Oscar","family":"Arrieta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis-Alberto","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Estrada-Lobato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura-Alejandra","family":"Ram\u00edrez-Tirado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor-Osvaldo","family":"Mendoza-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"de la Garza-Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,10]]},"reference":[{"issue":"3","key":"2477_CR1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ajim.20780","volume":"53","author":"G Aguilar-Madrid","year":"2010","unstructured":"Aguilar-Madrid G, Robles-P\u00e9rez E, Ju\u00e1rez-P\u00e9rez CA, Alvarado-Cabrero I, Rico-M\u00e9ndez FG, Javier KG (2010) Case\u2013control study of pleural mesothelioma in workers with social security in Mexico. Am J Ind Med 53(3):241\u2013251. doi: 10.1002\/ajim.20780","journal-title":"Am J Ind Med"},{"issue":"12","key":"2477_CR2","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1002\/1097-0142(19910615)67:12<2984::AID-CNCR2820671208>3.0.CO;2-Q","volume":"67","author":"A Ardizzoni","year":"1991","unstructured":"Ardizzoni A, Rosso R, Salvati F, Fusco V, Cinquegrana A, De Palma M, Serrano J, Pennucci MC, Soresi E, Crippa M, Gulisano M, Castagneto B, Scagliotti G, Rinaldi M (1991) Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study. Cancer 67(12):2984\u20132987","journal-title":"Cancer"},{"issue":"6","key":"2477_CR3","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/bjc.2012.44","volume":"106","author":"\u00d3 Arrieta","year":"2012","unstructured":"Arrieta \u00d3, Medina LA, Estrada-Lobato E, Hern\u00e1ndez-Pedro N, Villanueva-Rodr\u00edguez G, Mart\u00ednez-Barrera L, Macedo EO, L\u00f3pez-Rodr\u00edguez V, Motola-Kuba D, Corona-Cruz JF (2012) First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial. Br J Cancer 106(6):1027\u20131032. doi: 10.1038\/bjc.2012.44","journal-title":"Br J Cancer"},{"issue":"6","key":"2477_CR4","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1023\/A:1008346925273","volume":"11","author":"P Baas","year":"2000","unstructured":"Baas P, van Meerbeeck J, Groen H, Schouwink H, Burgers S, Daamen S, Giaccone G (2000) Caelyx\u2122 in malignant mesothelioma: a phase II EORTC study. Ann Oncol 11(6):697\u2013700","journal-title":"Ann Oncol"},{"issue":"3","key":"2477_CR5","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1378\/chest.114.3.713","volume":"114","author":"F B\u00e9nard","year":"1998","unstructured":"B\u00e9nard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A (1998) Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 114(3):713\u2013722","journal-title":"Chest"},{"issue":"2","key":"2477_CR6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1148\/radiol.10090714","volume":"255","author":"HW Head","year":"2010","unstructured":"Head HW, Dodd GD 3rd, Bao A, Soundararajan A, Garcia-Rojas X, Prihoda TJ, McManus LM, Goins BA, Santoyo CA, Phillips WT (2010) Combination radiofrequency ablation and intravenous radiolabeled liposomal doxorubicin: imaging and quantification of increased drug delivery to tumors. Radiology 255(2):405\u2013414. doi: 10.1148\/radiol.10090714","journal-title":"Radiology"},{"key":"2477_CR7","volume-title":"Mesothelioma in Great Britain 2013. Mesothelioma mortality in Great Britain 1968\u20132011","author":"Health and Safety Executive","year":"2013","unstructured":"Health and Safety Executive (2013) Mesothelioma in Great Britain 2013. Mesothelioma mortality in Great Britain 1968\u20132011. Health and Safety Executive, UK"},{"issue":"3","key":"2477_CR8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000216501","volume":"11","author":"H Henss","year":"1988","unstructured":"Henss H, Fiebig HH, Schildge J, Arnold H, Hasse J (1988) Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura. Onkologie 11(3):118\u2013120","journal-title":"Onkologie"},{"issue":"11","key":"2477_CR9","doi-asserted-by":"crossref","first-page":"816","DOI":"10.7150\/thno.6989","volume":"3","author":"S Ji","year":"2013","unstructured":"Ji S, Zheng Y, Shao G, Zhou Y, Liu S (2013) Integrin \u03b1v\u03b23-targeted radiotracer (99m)Tc-3P-RGD2 useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin \u03b1v\u03b23 RGD2 therapy. Theranostics 3(11):816\u2013830. doi: 10.7150\/thno.6989","journal-title":"Theranostics"},{"issue":"2","key":"2477_CR10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cllc.2012.09.003","volume":"14","author":"SC Kao","year":"2013","unstructured":"Kao SC, Lee K, Klebe S, Henderson D, McCaughan B, Vardy J, Clarke S, van Zandwijk N (2013) Excision repair cross complementation group 1 and thymidylate synthase expression in mesothelioma patients. Clin Lung Cancer 14(2):164\u2013171. doi: 10.1016\/j.cllc.2012.09.003","journal-title":"Clin Lung Cancer"},{"issue":"27","key":"2477_CR11","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1200\/JCO.2011.40.8120","volume":"30","author":"ES Kim","year":"2012","unstructured":"Kim ES, Lee JJ, He G, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Wistuba II, Stewart DJ, Siddik ZH (2012) Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol 30(27):3345\u20133352. doi: 10.1200\/JCO.2011.40.8120","journal-title":"J Clin Oncol"},{"issue":"3","key":"2477_CR12","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.lungcan.2008.09.008","volume":"64","author":"CW Lee","year":"2009","unstructured":"Lee CW, Murray N, Anderson H, Rao SC, Bishop W (2009) Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer 64(3):308\u2013313. doi: 10.1016\/j.lungcan.2008.09.008","journal-title":"Lung Cancer"},{"issue":"4","key":"2477_CR13","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/JTO.0b013e318283da3e","volume":"8","author":"DE Lustgarten","year":"2013","unstructured":"Lustgarten DE, Deshpande C, Aggarwal C, Wang LC, Saloura V, Vachani A, Wang LP, Litzky L, Feldman M, Creaney J, Nowak AK, Langer C, Inghilleri S, Stella G, Albelda SM (2013) Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma. J Thorac Oncol 8(4):469\u2013477. doi: 10.1097\/JTO.0b013e318283da3e","journal-title":"J Thorac Oncol"},{"key":"2477_CR14","doi-asserted-by":"crossref","unstructured":"Arrieta O, L\u00f3pez-Mac\u00edas D, Mendoza-Garc\u00eda VO, Bacon-Fonseca L, Mu\u00f1oz-Montalvo W, Macedo-P\u00e9rez EO,Mu\u00f1iz-Hern\u00e1ndez S, Blake-Cerda M, Corona-Cruz JF (2014) A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma. Cancer Chemother Pharmacol 73(5):975\u2013982. doi: 10.1007\/s00280-014-2429-5","DOI":"10.1007\/s00280-014-2429-5"},{"issue":"4","key":"2477_CR15","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ctrv.2012.11.004","volume":"39","author":"C Pinto","year":"2013","unstructured":"Pinto C, Novello S, Torri V, Ardizzoni A, Betta PG, Bertazzi PA, Casalini GA, Fava C, Fubini B, Magnani C, Mirabelli D, Papotti M, Ricardi U, Rocco G, Pastorino U, Tassi G, Trodella L, Zompatori M, Scagliotti G (2013) Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations. Cancer Treat Rev 39(4):328\u2013339. doi: 10.1016\/j.ctrv.2012.11.004","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"2477_CR16","first-page":"3441","volume":"29","author":"M Ralli","year":"2009","unstructured":"Ralli M, Tourkantonis I, Makrilia N, Gkini E, Kotteas E, Gkiozos I, Katirtzoglou N, Syrigos K (2009) Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study. Anticancer Res 29(8):3441\u20133444","journal-title":"Anticancer Res"},{"issue":"5","key":"2477_CR17","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1510\/icvts.2010.255901","volume":"12","author":"S Sharif","year":"2011","unstructured":"Sharif S, Zahid I, Routledge T, Scarci M (2011) Does positron emission tomography offer prognostic information in malignant pleural mesothelioma? Interact CardioVasc Thorac Surg 12(5):806\u2013811. doi: 10.1510\/icvts.2010.255901","journal-title":"Interact CardioVasc Thorac Surg"},{"issue":"1","key":"2477_CR18","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.bjc.6604421","volume":"99","author":"JB S\u00f8rensen","year":"2008","unstructured":"S\u00f8rensen JB, Frank H, Palshof T (2008) Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleuralmesothelioma. Br J Cancer 99(1):44\u201350. doi: 10.1038\/sj.bjc.6604421","journal-title":"Br J Cancer"},{"key":"2477_CR19","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"28","author":"JP Meerbeeck van","year":"2005","unstructured":"van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G (2005) European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 28:6881\u20136889","journal-title":"J Clin Oncol"},{"issue":"14","key":"2477_CR20","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14):2636\u20132644","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2477-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2477-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2477-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T14:54:58Z","timestamp":1716735298000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2477-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,10]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["2477"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2477-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,10]]}}}